Amphastar Pharmaceuticals, Inc. - Common Stock (NQ:AMPH)

25.81 +0.27 (+1.06%)

Delayed Quote Updated: 4:00 PM EDT, Oct 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amphastar Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Exelixis Stock Generating Improved Relative Strength Rating ↗

March 16, 2023

Exelixis stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, with an upgrade from 69 to 76.

Via Investor's Business Daily

Vertex Pharmaceuticals Stock Gets Technical Rating Upgrade ↗

March 13, 2023

Vertex Pharmaceuticals stock saw a positive improvement to its Relative Strength (RS) Rating on Monday, rising from 67 to 77.

Via Investor's Business Daily

Amphastar Pharmaceuticals Receives FDA Approval for Naloxone Hydrochloride Nasal Spray 4mg

March 08, 2023

Via ACCESSWIRE

Kala Pharmaceuticals Stock Showing Rising Market Leadership; Earns 83 RS Rating ↗

March 03, 2023

On Friday, Kala Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded to 83, up from 67 a day earlier.

Via Investor's Business Daily

Why Shares of Amphastar Pharmaceuticals Rose Today ↗

March 01, 2023

The company reported a record revenue year and increased EPS.

Via The Motley Fool

3D Systems, CarGurus, Sarepta Therapeutics And Other Big Stocks Moving Higher On Wednesday ↗

March 01, 2023

U.S. stocks traded lower, with the Dow Jones dropping around 80 points on Wednesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Earnings Outlook For Amphastar Pharmaceuticals ↗

February 27, 2023

Via Benzinga

Why Novavax Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

March 01, 2023

Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) shares jumped 171.5% to $84.67 after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia.

Via Benzinga

Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2023

February 22, 2023

Via ACCESSWIRE

Amphastar Pharmaceuticals to Present at the Piper Sandler 34th Annual Healthcare Conference

November 22, 2022

Via ACCESSWIRE

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2022

November 07, 2022

Via ACCESSWIRE

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2022

August 08, 2022

Via ACCESSWIRE

Can This Company's Positive Results For Psychedelic Combination Treatment Provide Hope For Alcohol And Cocaine Addiction Problems? ↗

November 15, 2022

There is a high probability that you may know someone battling some form of addiction. Whether it’s a problem with opioids, alcohol, cocaine, or even using pain meds, an unchecked addiction can be...

Via Benzinga

Amphastar Pharmaceuticals to Present at the 2022 Jefferies London Healthcare Conference

November 10, 2022

Via ACCESSWIRE

Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 7, 2022

October 28, 2022

Via ACCESSWIRE

Intercept Pharmaceutical Stock Sees RS Rating Rise To 91 ↗

September 27, 2022

Intercept Pharmaceutical shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Via Investor's Business Daily

Recursion Pharma Stock Earns Relative Strength Rating Upgrade; Hits Key Benchmark ↗

September 26, 2022

Recursion Pharma stock cleared a key performance benchmark Monday, with its Relative Strength Rating upgraded to 89 from 76 the day before.

Via Investor's Business Daily

7 Safe Stocks to Rely on When the Market Swerves ↗

September 19, 2022

As volatility and uncertainty continue, it remains a good time to add these seven safe stocks to your portfolio.

Via InvestorPlace

Amphastar Pharmaceuticals to Present at the Wells Fargo 2022 Healthcare Conference

September 02, 2022

Via ACCESSWIRE

Amphastar Pharmaceuticals's Return on Invested Capital Overview ↗

August 29, 2022

Pulled from Benzinga Pro data, Amphastar Pharmaceuticals (NASDAQ:AMPH) showed a loss in earnings since Q1, totaling $17.35 million. Sales, on the other hand, increased by 2.57% to $123.47 million...

Via Benzinga

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary ↗

August 16, 2022

Via Benzinga

Amphastar Pharmaceuticals Receives FDA Approval for Epinephrine Pre-Filled Syringes

August 16, 2022

Via ACCESSWIRE

Stock Market Rally Rises On Inflation Data; Nvidia, Micron, Tesla, Disney In Focus: Weekly Review ↗

August 12, 2022

The major indexes continued to advance, despite some key warnings.

Via Investor's Business Daily

Amphastar Pharmaceuticals: Q2 Earnings Insights ↗

August 08, 2022

Amphastar Pharmaceuticals (NASDAQ:AMPH) reported its Q2 earnings results on Monday, August 8, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Amphastar, Syndax Top Second-Quarter Estimates, But Runaway Biotechs At A Standstill ↗

August 08, 2022

Amphastar came in well above forecasts, while Syndax had fewer than expected losses.

Via Investor's Business Daily

Kura Oncology Stock Joins Rank Of Stocks With RS Ratings Over 90 ↗

August 08, 2022

On Monday, Kura Oncology stock had its Relative Strength (RS) Rating upgraded to 91, up from 85 a day earlier.

Via Investor's Business Daily

Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2022

August 01, 2022

Via ACCESSWIRE

Benzinga's Top Ratings Upgrades, Downgrades For July 29, 2022 ↗

July 29, 2022

Via Benzinga

Keep Amphastar Pharmaceuticals Stock On Your Watch List Ahead Of Earnings ↗

July 26, 2022

IBD 50 member Amphastar Pharmaceuticals stock is expected to report on Aug. 9 and is trading approximately 12% below a 42.41 entry.

Via Investor's Business Daily

Amphastar Receives FDA Approval for Vasopressin

July 19, 2022

Via ACCESSWIRE

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.